Home / Conferences

Conferences

European Commission calls for wider use of generic medicines

At the 10th International Symposium on Biosimilar Medicines, organised by the European Generics medicines Association, held in London, UK, on 19–20 April 2012; the European Commission (EC) highlighted the need to stimulate wider use of generic medicines.

Removal of barriers for the global development of biosimilars

At the 2012 Biosimilars Medicines: 10th EGA International Symposium, held in London, UK, on 19–20 April 2012; Mr Nils Behrndt (Deputy Head of Cabinet DG Sanco, European Commission) announced that the European Commission (EC) wishes to stimulate the global development of biosimilars. The EC has thereby two objectives:

Europe must seize new opportunities in biosimilars and generics

Opportunities for increased employment and growth in the generic and biosimilar medicines markets should be exploited in order to avoid Europe falling behind other regions according to the European Generic medicines Association (EGA).

EGA meeting London 2011: biosimilars competitiveness in the EU

At its 9th International Symposium on Biosimilar Medicines held in London, UK, on 14-15 April 2011 the European Generic medicines Association (EGA) highlighted the need for an EU industrial policy to enhance the competitiveness of biosimilars.

Pharmacokinetics, bioequivalence of cyclobenzaprine tablets

Cyclobenzaprine is a muscle relaxant, structurally related to first-generation tricyclic antidepressants. At the 2008 World Congress of Pharmacy and Pharmaceutical Sciences held 29 August – 4 September 2008 in Basel, Switzerland, Ms Tatiane Maria de Lima Souza Brioschi et al. of the University of Sao Paolo in Brazil presented a poster entitled ‘Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets’ in which the bioequivalence of two brands of cyclobenzaprine 10 mg tablets in healthy volunteers was evaluated.

Bioavailability and bioequivalence norms in Latin America

At the 2008 World Congress of Pharmacy and Pharmaceutical Sciences held 29 August – 4 September 2008 in Basel, Switzerland, Mr Luis Enrique Morena Exebio of the National Institutes of Health (NIH) in Peru, presented a poster entitled ‘Investigation’s ethical aspects regarding pharmaceutical products bioavailability and bioequivalence in Latin American legislation’.

Overcoming protein-production hurdles: Glycosylation

In a Genetic Engineering & Biotechnology News Feature Article of 1 June 2009, Mr John Morrow Jr discusses protein-production hurdles for biologicals, which was a key theme at IBC’s “Bioprocessing Meeting”, held in La Costa, CA, USA in 2009.

Overcoming protein-production hurdles: Expression systems

In a Genetic Engineering & Biotechnology News Feature Article of 1 June 2009, Mr John Morrow Jr discusses protein-production hurdles for biologicals, which was a key theme at IBC’s ‘Bioprocessing Meeting’, held in La Costa, CA, USA in 2009.

EGA meeting Barcelona 2009: Big Pharma must not underestimate generics

Big Pharma moving into generic medicines may seem like a shrewd move, but it is not necessarily a recipe for success, Ms Francesca Bruce of Scrip News heard at the European Generic medicines Association (EGA) conference recently held in Barcelona, Spain.

EGA: Biosimilars essential for generics industry as well

Would-be big generics players will have to move into biosimilars, Ms Francesca Bruce of Scrip News heard at the European Generic medicines Association (EGA) conference recently held in Barcelona, Spain.

Generics News Research General

more

Biosimilars News Research General

more